LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 65.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,083 shares of the medical instruments supplier’s stock after selling 15,389 shares during the quarter. Bridgewater Associates LP’s holdings in LeMaitre Vascular were worth $751,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its position in shares of LeMaitre Vascular by 14.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,643 shares of the medical instruments supplier’s stock worth $375,000 after acquiring an additional 695 shares in the last quarter. GAMMA Investing LLC raised its position in LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of LeMaitre Vascular by 240.2% during the second quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock worth $929,000 after purchasing an additional 7,976 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its position in shares of LeMaitre Vascular by 3.4% in the second quarter. Linden Thomas Advisory Services LLC now owns 31,560 shares of the medical instruments supplier’s stock worth $2,597,000 after buying an additional 1,034 shares during the period. Finally, OLD National Bancorp IN acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at about $228,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 1.4 %

Shares of NASDAQ LMAT opened at $105.47 on Tuesday. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 57.63, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. LeMaitre Vascular, Inc. has a twelve month low of $52.55 and a twelve month high of $109.58. The business has a 50 day simple moving average of $95.80 and a 200-day simple moving average of $88.23.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the previous year, the firm earned $0.33 earnings per share. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, JMP Securities increased their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.